Knowledgebase

OUR BEST-IN-CLASS, IVD-GRADE VARIANT INTERPRETATION KNOWLEDGE BASE

Powering our Clinical Genomics Workspace decision support software, our knowledge base ensures your patients get the latest and greatest knowledge to support the optimum treatment decision.

Request a demo

The Clinical Genomics Knowledgebase at a glance

With the continuous expansion of medical knowledge and new therapies, clinical labs face an overwhelming volume of genetic data that requires fast yet accurate interpretation. The Velsera Clinical Genomics Knowledgebase – a key feature of the Clinical Genomics Workspace – addresses this challenge by combining advanced technology with human expertise to build a knowledge base of clinical interpretations that enable laboratories to engage in the practice of medicine and assemble clinical content for each patient.

Why use Velsera’s Clinical Genomics Knowledge Base

Simply the best.

Breadth of knowledge

With over 400,000 logical rules covering 1,250 somatic cancer genes, the Velsera Knowledgebase supports all major genomic variant types—including SNVs, TMB, MSI, indels, CNVs, fusions, and large structural variants—ensuring robust support for complex genomic testing scenarios.

Depth of knowledge

The Velsera Clinical Genomics Knowledgebase draws from a wide array of sources to ensure precise variant interpretation, including:

FDA and EMA drug labels
Oncology practice guidelines (NCCN, ASCO, ESMO)
Clinical trials from clinicaltrials.gov and the European Clinical Trial Register
Real-world medical data through the Velsera Clinical Sharing Network
Public data sources such as COSMIC, TCGA, and ClinVar

This diverse dataset is continuously curated by Velsera’s team of PhD- and MS-level scientists, ensuring users can confidently interpret even the most complex genomic variants.

Most up-to-date

Velsera's expert biocurators continuously review and update the knowledgebase, ensuring users have access to the latest clinical insights. Each update is rigorously verified, following SOPs designed to meet ISO 13485, ensuring that every patient report is backed by trustworthy, up-to-date evidence. Our team of expert biocurators make monthly updates to our knowledge base which are pushed out to all of our CGW users.

Most actionable

Unlike simple variant lookups, Velsera’s Knowledgebase leverages a flexible metadata model and rules engine that allows for comprehensive content matching. Whether the variant has been previously described or not, the system applies logic based on gene-variant-disease patterns to generate meaningful interpretations. This future-proofs the platform for emerging biomarkers and evolving genomic technologies.

Who we help accelerate

Customers for this technology

Clinical Diagnostic Laboratories

Accelerate the scale-up of your NGS testing

Grow revenue by expanding your NGS business. Velsera helps diagnostic labs rapidly establish and grow new, profitable NGS revenue streams. With our support, we can help your lab get up-and-running with an existing on-market assay (20+ LDT & IVD options available), including support for validation, revenue cycle management, and our Clinical Genomics Workspace (CGW) software to aid clinical decision-making.

Learn more

NGS Assay & Equipment Manufacturers

Bring new tests and equipment to market

Have you got a promising diagnostic test in development? Or do you have novel equipment that you want to drive uptake of in the clinical setting? Velsera can partner with you to bring new, promising tests to market by creating, integrating, hosting and/or deploying custom-developed NGS analysis pipelines. Additionally, we can help your future laboratory customers with validation and regulatory support to ensure compliance, as well as Revenue Cycle Management support to enable reimbursement – increasing the uptake from customers. Optionally, tertiary CGW reporting is available to create a fully integrated secondary & tertiary analysis package for your test.

Learn more

Biotech & Pharma

Accelerate uptake of your upcoming launch

Don’t wait until the last minute to design and develop your Companion Diagnostic (CDx) – it literally is the rate limiting gate keeper to scaling your new therapy! Velsera can partner with you to design and develop your test by creating, integrating, hosting and/or deploying custom-developed NGS analysis pipelines. Additionally, once live in the market, we can help labs with validation and regulatory support to ensure compliance, as well as Revenue Cycle Management support to enable reimbursement – increasing the uptake from customers. Optionally, tertiary CGW reporting is available to create a fully integrated secondary & tertiary analysis package for your test.

Learn more

Solutions

Solutions this platform supports

Clinical Interpretation & Reporting

ACCELERATE THE SCALE-UP OF YOUR NGS TESTING

Learn more

NGS Assay Development & Expansion

DEVELOP NEW TESTS TO MEET UNMET NEEDS

Has your lab recognized an unmet need in the market? Velsera helps ambitious diagnostic labs generate revenue by creating, integrating, hosting and/or deploying custom-developed NGS analysis pipelines. Additionally, we help with validation and regulatory support to ensure compliance, as well as Revenue Cycle Management support to enable reimbursement. Optionally, tertiary CGW reporting is available to create a fully integrated secondary & tertiary analysis package for your test.

Learn more

IVD Compliance Transition

NAVIGATE REGULATORY UNCERTAINTY

Don’t let compliance challenges impede your progress. Velsera assists labs in navigating the FDA clearance process for both new assays and existing Laboratory Developed Tests (LDTs). We provide the necessary “dry-lab” component for approved products, along with optional tertiary reporting to enhance your workflow.

Learn more

Companion diagnostic development & scaling

ACCELERATE UPTAKE OF YOUR UPCOMING LAUNCH

Learn more

Real-world impact, trusted partnerships

“I knew that with the resources we had, there was no way to create something that would rival a system like the CGW. As we've set up reflex testing in various cancer types, we have been well supported to scale the massive undertaking.”

Nikoletta Sidiropoulos, MD

Medical Director / University of Vermont Medical Center